<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did OCUL's revenue and expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/14/2025 06:29pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Ocular Therapeutix (OCUL) experienced a significant decline in net income in Q4 2024, with a net loss of $48.39 million, despite a total revenue of $17.08 million. The R&amp;D expenses were notably high at $40.99 million for the quarter.


|code|Ticker|Name|Date|R&amp;D Expenses|Total Revenue|Net Income|market_code|
|---|---|---|---|---|---|---|---|
|OCUL|OCUL.O|Ocular Therapeutix|2024 Q1|2.0735E7|1.4774E7|-6.4848E7|185|
|OCUL|OCUL.O|Ocular Therapeutix|2024 Q2|2.8857E7|1.6441E7|-4.3777E7|185|
|OCUL|OCUL.O|Ocular Therapeutix|2024 Q3|3.7054E7|1.5425E7|-3.6493E7|185|
|OCUL|OCUL.O|Ocular Therapeutix|2024 Q4|4.0989E7|1.7082E7|-4.8388E7|185|

</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw){return {layout:"default",data:[{noData:c,currentQuestion:g,textDescription:V,comeFrom:"AInvestShareLink",events:[],answerSource:o}],fetch:{},error:p,state:{sharePreviewModule:{loadJgySuccess:d,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:h,agent_id:a,output_media_info:[],task_id:a,language:a,source:o,cache_builder:a,reply_action:"Answer",execute_mode:I,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did OCUL's revenue and expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did OCUL's revenue and expenses trend in Q4 2024?\",\"user_id\":\"dp22624819\",\"user_name\":\"\",\"trace_id\":\"14bf4c1f-13dc-42a1-b3b4-e380c6824943\",\"session_id\":\"14bf4c1f-13dc-42a1-b3b4-e380c6824943\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:j,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Total Revenue[20241231]|R&D Expenses[20241231]|Total Expenses[20241231]|Net Income[20241231]|Report End Date|\n|---|---|---|---|---|---|---|---|---|\n|OCUL|Ocular Therapeutix|$7.11|11.01%|$17.08 million|$40.99 million||-$48.39 million|20241231|\n",query_data:{number:h,title:J,query_type:j,condition:a,model_sql:W,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d}}}],answer_chain_name:X,agent_mode:Y,native_answer:a,come_from:a,text_answer:V,trace_id:i,cost:18000,event_names:a,question:g,fallback_type:Z,input_type:_,fall_back_reason:{fall_back_type:Z,risk_detail:{matched_words:[]}},session_id:i,first_return_cost:3492,cache_type:a,question_id:i,transfer_question:g,signal_type:"ON_COMPLETE",start_time:$,remote_svc:o,slots:[],answer_type:I,user_id:z,skill_name:K},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:i,session_id:i,user_id:z,question:g,source:o,raw_question:g,version:"3.4.1",action_name:K,nlu:{entity:[{type:aa,value:q,market:k}]},deep_research:c,deep_thinking:c,agent_mode:Y},extra:{}},{answer_path:A,section:{id:B,info_texts:["Thinking"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:A,section:{id:B,info_texts:["Querying Stock: OCUL Revenue (Q4 2024), R&D Expenses (Q4 2024), SG&A Expenses (Q4 2024), Net Income (Q4 2024)"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:J,thought:"The user seeks to analyze OCUL's Q4 2024 revenue and expense trends. I should focus on its Q4 2024 revenue, R&D expenses, SG&A expenses, and net income data. I will use FinQuery for the data mentioned above."}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:A,section:{id:B,info_texts:["Generating Answer"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:D,voice_txt:"O",text_answer:ab,rich_text:ab,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:2000,info_texts:[],show_type:D,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:J,query_type:j,trace_data:a,index:h,model_sql:W,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:D,voice_txt:".\n\n",text_answer:ac,rich_text:ac,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:t,market_id:k,name:m,domain:aa},pos:d,section_id:s,txt:m,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:ad,choice:[],result_page:{components:[{uuid:"48dc8682baa77874",config:{score:116,show_type:ae,scoreRuleNames:"value_unit;data_size;",showDataZoom:b,show_type_id:131,title:"分组柱状图",render:{x:u,y:[E,F,G]},title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:af,h2:a},show_type:L}},data:{chunks_info:"[]",code_count:h,columns:[{index_name:M,key:M,label:"hq_code",source:N,type:f},{domain:v,feKey:O,index_name:O,key:O,label:M,origin_index:"stock code",source:N,type:f,unit:a},{domain:v,feKey:P,index_name:P,key:P,label:"name",origin_index:"stock name",source:N,type:f,unit:a},{feKey:u,index_name:u,key:u,label:"date",origin_index:u,type:"DATE"},{domain:v,feKey:E,index_name:E,key:E,label:a,source:a,timestamp:a,type:Q,unit:R},{domain:v,feKey:F,index_name:F,key:F,label:a,source:a,timestamp:a,type:Q,unit:R},{domain:v,feKey:G,index_name:G,key:G,label:a,source:a,timestamp:a,type:Q,unit:R},{index_name:ag,key:ag,type:f}],condition:"[{\"sonSize\":6,\"opName\":\"and\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"indexProperties\":[\"EQUAL OCUL.O\"],\"indexPropertiesMap\":{\"EQUAL\":\"OCUL.O\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":4,\"opName\":\"or\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@R\\u0026D Expenses\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Net Income\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Total Revenue\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"domain\":\"abs_国际美股领域\",\"relatedSize\":0}]",dataSize:4,datas:[{"Net Income":-64848000,code:t,"R&D Expenses":20735000,"Total Revenue":14774000,Ticker:q,market_code:k,Date:"2024 Q1",Name:m},{"Net Income":-43777000,code:t,"R&D Expenses":28857000,"Total Revenue":16441000,Ticker:q,market_code:k,Date:"2024 Q2",Name:m},{"Net Income":-36493000,code:t,"R&D Expenses":37054000,"Total Revenue":15425000,Ticker:q,market_code:k,Date:"2024 Q3",Name:m},{"Net Income":-48388000,code:t,"R&D Expenses":40989000,"Total Revenue":17082000,Ticker:q,market_code:k,Date:"2024 Q4",Name:m}],meta:{extra:{}},row_count:h,status_code:d,status_msg:"ok"},category:"generic",chart_type:"groupedBar",show_type:ae,title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:af,h2:a},show_type:L},support_refresh:b,data_config:{query:a,query_type:j,data_ext_params:{}}}],global:{query_type:j},page:{language:a,layout:{layout_data:"[{\"children\":[],\"showType\":\"bar3\",\"uuid\":\"48dc8682baa77874\"}]"},render_for:S},data_config:{query:a,query_type:j,data_ext_params:{}}},tag_info_list:[],is_last:c,uuid:"a75dd997-2f38-4e74-b79e-c30aa0ee264e"},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:D,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:A,section:{id:B,info_texts:["Completed"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:ad,choice:[{display_text:w,query_text:w,trace_info:{item_id:"ab40e8e9e9e56e344d6082dd4f5d89fe",item_type:n,item_name:w,rec_info:ah}},{display_text:x,query_text:x,trace_info:{item_id:"6a4b2b74077e9f101b7e0009567b3f56",item_type:n,item_name:x,rec_info:ai}},{display_text:y,query_text:y,trace_info:{item_id:"8e0da03425eba1ca2a2d7a851360a8f5",item_type:n,item_name:y,rec_info:aj}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:L,data:{h1:a,h2:a},config:{display:c,txt_style:d,type:"1",display2:c,url:a}},request_config:[{source_type:ak,related_name:al}],puuid:T,tag:a,category:"custom",uuid:am}],global:{urp_static_data:[{name:al,value:{status_code:d,columns:[{type:f,index_name:an,key:an},{type:f,index_name:ao,key:ao},{type:f,index_name:ap,key:ap},{type:f,index_name:aq,key:aq},{type:f,index_name:ar,key:ar}],datas:[{send_text:w,item_type:n,rec_info:ah,display_text:w,rec_reason:a},{send_text:x,item_type:n,rec_info:ai,display_text:x,rec_reason:a},{send_text:y,item_type:n,rec_info:aj,display_text:y,rec_reason:a}],dataSize:ak,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:as,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:H,"min-height":"100%",position:at,height:H},isMaterial:c,id:as,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:d,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:U,componentUuid:am,script:[{name:au,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:U,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:U},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:H,position:at,height:H},isMaterial:b,_id:19,id:au,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:S,voice_txt:a,tracking_info:{},uuid:T},order:{is_auto:c,render_for:S,chart_type:"command",puuid:T}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:K,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:I,answer_chain_name:X},is_deep_research:c,deep_thinking:c,create_time:1744626596747},is_last:b}],questionItem:{data:{qStr:g,encodeFlag:c,imageData:p,docsData:[],quoteData:p},tplType:"question"},events:av,agentId:a,param:{entity_info:{},add_info:{ori_question:g},event_list:av,client_ip:a,question:g,user_id:z,user_name:a,trace_id:i,session_id:i,source:o,input_type:_}}],userId:z,userName:a,startTime:$,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:p,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:d,traceTableData:p,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-oculs-revenue-and-expenses-trend-in-q4-2024-1e6b7f\u002F",config:{_app:{basePath:aw,assetsPath:aw,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,0,"other\u002FopenAnswer","STR","How did OCUL's revenue and expenses trend in Q4 2024?",1,"14bf4c1f-13dc-42a1-b3b4-e380c6824943","intusstock","185","signal","Ocular Therapeutix","llm_generated","ths_ainvest_lite_web",null,"OCUL.O",999,2001,"OCUL","Date","abs_国际美股领域","💼 What was OCUL's net income for Q4 2024?","🔎 What were OCUL's revenue figures for Q4 2024?","📊 How does OCUL's Q4 2024 financial performance compare to analyst expectations?","dp22624819","progress\u002Fsearching_for",1000,"searching_for","rich_text","R&D Expenses","Total Revenue","Net Income","auto","agent","OCUL Revenue (Q4 2024), R&D Expenses (Q4 2024), SG&A Expenses (Q4 2024), Net Income (Q4 2024)","review stocks","title1","code","fixed_index","Ticker","Name","DOUBLE","USD","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Ocular Therapeutix (OCUL) experienced a significant decline in net income in Q4 2024, with a net loss of $48.39 million, despite a total revenue of $17.08 million. The R&D expenses were notably high at $40.99 million for the quarter.\n\n\n|code|Ticker|Name|Date|R&D Expenses|Total Revenue|Net Income|market_code|\n|---|---|---|---|---|---|---|---|\n|OCUL|OCUL.O|Ocular Therapeutix|2024 Q1|2.0735E7|1.4774E7|-6.4848E7|185|\n|OCUL|OCUL.O|Ocular Therapeutix|2024 Q2|2.8857E7|1.6441E7|-4.3777E7|185|\n|OCUL|OCUL.O|Ocular Therapeutix|2024 Q3|3.7054E7|1.5425E7|-3.6493E7|185|\n|OCUL|OCUL.O|Ocular Therapeutix|2024 Q4|4.0989E7|1.7082E7|-4.8388E7|185|\n\n","select   stock_code,   total_revenue,   r_d_expenses,   total_expenses,   net_income from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'OCUL.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1744626578747,"stock","Ocular Therapeutix (OCUL) experienced a significant decline in net income in Q4 2024, with a net loss of $48.39 million, despite a total revenue of $17.08 million. The R&D expenses were notably high at $40.99 million for the quarter[^1]",".\n\n\n``` visual\n{\"uuid\":\"a75dd997-2f38-4e74-b79e-c30aa0ee264e\"}\n```","result_page","bar3","OCUL R&D Expenses, Total Revenue...","market_code","2+679_496_21_554+0+0+14bf4c1f-13dc-42a1-b3b4-e380c6824943+ab40e8e9e9e56e344d6082dd4f5d89fe+llm_generated+aimeTagAnalysis+0+0.13250231742858887+1","2+679_496_21_554+0+0+14bf4c1f-13dc-42a1-b3b4-e380c6824943+6a4b2b74077e9f101b7e0009567b3f56+llm_generated+aimeTagAnalysis+0+0.11188425868749619+2","2+679_496_21_554+0+0+14bf4c1f-13dc-42a1-b3b4-e380c6824943+8e0da03425eba1ca2a2d7a851360a8f5+llm_generated+aimeTagAnalysis+0+0.06594030559062958+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>